Survivin-driven and fiber-modified oncolytic adenovirus exhibits potent antitumor activity in established intracranial glioma

Human Gene Therapy

Volumn 18, Issue 7, 2007, Pages 589-602

  Ulasov, Ilya V ^a   Zhu, Zeng B ^b   Tyler, Matthew A ^a   Han, Yun ^a   Rivera, Angel A ^b   Khramtsov, Andrey ^a   Curiel, David T ^b   Lesniak, Maciej S ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHAVBETA5 INTEGRIN; MICROSOMAL AMINOPEPTIDASE; PROTEOHEPARAN SULFATE; SURVIVIN; VITRONECTIN RECEPTOR;

ADENOVIRUS 5; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GENE THERAPY; CANCER INHIBITION; CONTROLLED STUDY; FEMALE; GLIOMA; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; ONCOLYTIC VIROTHERAPY; TISSUE SPECIFICITY; TUMOR XENOGRAFT; VIRUS REPLICATION;

ADENOVIRIDAE; ANIMALS; BLOTTING, WESTERN; BRAIN NEOPLASMS; CAPSID PROTEINS; CELL LINE, TUMOR; FEMALE; GENE THERAPY; GENETIC VECTORS; GLIOMA; HUMANS; IMMUNOHISTOCHEMISTRY; INJECTIONS, INTRALESIONAL; MICE; MICE, NUDE; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; ONCOLYTIC VIROTHERAPY; PROMOTER REGIONS (GENETICS); TREATMENT OUTCOME; VIRUS REPLICATION;

ADENOVIRIDAE; MUS;

EID: 34547523121     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.2007.002     Document Type: Article

References (46)

1. ALANKO, T., TIENARI, J., LEHTONEN, E., and SAKSELA, O. (1994). Development of FGF-dependency in human embryonic carcinoma cells after retinoic acid-induced differentiation. Dev. Biol. 161, 141-153.
2. ASAOKA, K., TADA, M., SAWAMURA, Y., IKEDA, J., and ABE, H. (2000). Dependence of efficient adenoviral gene delivery in malignant glioma cells on the expression levels of the coxsackievirus and adenovirus receptor. J. Neurosurg. 92, 1002-1008.
3. CHAKRAVARTI, A., NOLL, E., BLACK, P.M., FINKELSTEIN, D.F., FINKELSTEIN, D.M., DYSON, N.J., and LOEFFLER, J.S. (2002). Quantitatively determined survivin expression levels are of prognostic value in human gliomas. J. Clin. Oncol. 20, 1063-1068.
4. CHAKRAVARTI, A., ZHAI, G.G., ZHANG, M., MALHOTRA, R., LATHAM, D.E., DELANEY, M.A., ROBE, P., NESTLER, U., SONG, Q., and LOEFFLER, J. (2004). Survivin enhances radiation resistance in primary human glioblastoma cells via caspase-independent mechanisms. Oncogene 23, 7494-7506.
5. CHIOCCA, E.A., ABBED, K.M., TATTER, S., LOUIS, D.N., HOCHBERG, F.H., BARKER, F., KRACHER, J., GROSSMAN, S.A., FISHER, J.D., CARSON, K., ROSENBLUM, M., MIKKELSEN, T., OLSON, J., MARKERT, J., ROSENFELD, S., NABORS, L.B., BREM, S., PHUPHANICH, S., FREEMAN, S., KAPLAN, R., and ZWIEBEL, J, (2004). A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting. Mol. Ther. 10, 958-966.
6. CONRAD, C., MILLER, C.R., JI, Y., GOMEZ-MANZANO, C., BHARARA, S., McMURRAY, J.S., LANG, F.F., WONG, F., SAWAYA, R., YUNG, W.K., and FUEYO, J. (2005). Δ24-hyCD adenovirus suppresses glioma growth in vivo by combining oncolysis and chemosensitization. Cancer Gene Ther. 12, 284-294.
7. CRIPE, T.P., DUNPHY, E.J., HOLUB, A.D., SAINI, A., VASI, N.H., MAHLLER, Y.Y., COLLINS, M.H., SNYDER, J.D., KRASNYKH, V., CURIEL, D.T., WICKHAM, T.J., DEGREGORI, J., BERGELSON, J.M., and CURRIER, M.A. (2001). Fiber knob modifications overcome low, heterogeneous expression of the coxsackievirus- adenovirus receptor that limits adenovirus gene transfer and oncolysis for human rhabdomyosarcoma cells. Cancer Res. 61, 2953-2960.
8. DMITRIEV, I., KRASNYKH, V., MILLER, C.R., WANG, M., KASHENTSEVA, E., MIKHEEVA, G., BELOUSOVA, N., and CURIEL, D.T. (1998). An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a cox-sackievirus and adenovirus receptor-independent cell entry mechanism. J. Virol. 72, 9706-9713.
9. FUEYO, J., GOMEZ-MANZANO, C., ALEMANY, R., LEE, P.S., McDONNELL, T.J., MITLIANGA, P., SHI, Y.X., LEVIN, V.A., YUNG, W.K., and KYRITSIS, A.P. (2000). A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene 19, 2-12.
10. FUXE, J., LIU, L., MALIN, S., PHILIPSON, L., COLLINS, V.P., and PETTERSSON, R.F. (2003). Expression of the coxsackie and adenovirus receptor in human astrocytic tumors and xenografts. Int. J. Cancer 103, 723-729.
11. GEOERGER, B., GRILL, J., OPOLON, P., MORIZET, J., AUBERT, G., TERRIER-LACOMBE, M.J., BRESSAC DE-PAILLERETS, B., BARROIS, M., FEUNTEUN, J., KIRN, D.H., and VASSAL, G. (2002). Oncolytic activity of the E1B-55 kDa-deleted adenovirus ONYX-015 is independent of cellular p53 status in human malignant glioma xenografts. Cancer Res. 62, 764-772.
12. GEOERGER, B., GRILL, J., OPOLON, P., MORIZET, J., AUBERT, G., LECLUSE, Y., VAN BEUSECHEM, V.W., GERRITSEN, W.R., KIRN, D.H., and VASSAL, G. (2003). Potentiation of radiation therapy by the oncolytic adenovirus d11520 (ONYX-015) in human malignant glioma xenografts. Br. J. Cancer 89, 577-584.
13. GINGIS-VELITSKI, S., ZETSER, A., KAPLAN, V., BEN-ZAKEN, O., COHEN, E., LEVY-ADAM, F., BASHENKO, Y., FLUGELMAN, M.Y., VLODAVSKY, I., and ILAN, N. (2004). Heparanase uptake is mediated by cell membrane heparan sulfate proteoglycans. J. Biol. Chem. 279, 44084-44092.
14. GRAHAM, F.L., SMILEY, J., RUSSELL, W.C., and NAIRN, R. (1977). Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J. Gen. Virol. 36, 59-74.
15. HSIEH, J.C., and LESNIAK, M.S. (2005). Surgical management of high-grade gliomas. Expert Rev. Neurother. 5, S33-S39.
16. HSU, W., LESNIAK, M.S., TYLER, B., and BREM, H. (2005). Local delivery of interleukin-2 and Adriamycin is synergistic in the treatment of experimental malignant glioma. J. Neurooncol. 74, 135-140.
17. IMMONEN, A., VAPALAHTI, M., TYYNELA, K., HURSKAINEN, H., SANDMAIR, A., VANNINEN, R., LANGFORD, G., MURRAY, N., and YLA-HERTTUALA, S. (2004). AdvHSV-tk gene therapy with intravenous ganciclovir improves survival in human malignant glioma: A randomised, controlled study. Mol. Ther. 10, 967-972.
18. KAJIWARA, Y., YAMASAKI, F., HAMA, S., YAHARA, K., YOSHIOKA, H., SUGIYAMA, K., ARITA, K., and KURISU, K. (2003). Expression of survivin in astrocytic tumors: Correlation with malignant grade and prognosis. Cancer 97, 1077-1083.
19. KANERVA, A., BAUERSCHMITZ, G.J., YAMAMOTO, M., LAM, J.T., ALVAREZ, R.D., SIEGAL, G.P., CURIEL, D.T., and HEMMINKI, A. (2004). A cyclooxygenase-2 promoter-based conditionally replicating adenovirus with enhanced infectivity for treatment of ovarian adenocarcinoma. Gene Ther. 11, 552-559.
20. KIRBY, T.O., RIVERA, A., REIN, D., WANG, M., ULASOV, I., BREIDENBACH, M., KATARAM, M., CONTRERAS, J.L., KRUMDIECK, C., YAMAMOTO, M., ROTS, M.G., HAISMA, H.J., ALVAREZ, R.D., MAHASRESHTI, P.J., and CURIEL, D.T. (2004). A novel ex vivo model system for evaluation of conditionally replicative adenoviruses therapeutic efficacy and toxicity. Clin. Cancer Res. 10, 8697-8703.
21. LAMFERS, MX., GRILL, J., DIRVEN, CM., VAN BEUSECHEM, V.W., GEOERGER, B., VAN DEN BERG, J., ALEMANY, R., FUEYO, J., CURIEL, D.T., VASSAL, G., PINEDO, H.M., VANDERTOP, W.P., and GERRITSEN, W.R. (2002). Potential of the conditionally replicative adenovirus Ad5-Δ24RGD in the treatment of malignant gliomas and its enhanced effect with radiotherapy. Cancer Res. 62, 5736-5742.
22. LESNIAK, M.S. (2005). Novel advances in drug delivery to brain cancer. Technol. Cancer Res. Treat. 4, 417-428.
23. LESNIAK, M.S., and BREM, H. (2004). Targeted therapy for brain tumours. Nat. Rev. Drug Discov. 3, 499-508.
24. LESNIAK, M.S., LANGER, R., and BREM, H. (2001). Drug delivery to tumors of the central nervous system. Curr. Neurol. Neurosci. Rep. 1, 210-216.
25. LESNIAK, M.S., UPADHYAY, U., GOODWIN, R., TYLER, B., and BREM, H. (2005). Local delivery of doxorubicin for the treatment of malignant brain tumors in rats. Anticancer Res. 25, 3825-3831.
26. MURPHY, P.R., and KNEE, R.S. (1995). Basic fibroblast growth factor binding and processing by human glioma cells. Mol. Cell. Endocrinol. 114, 193-203.
27. PORTELLA, G., SCALA, S., VITAGLIANO, D., VECCHIO, G., and FUSCO, A. (2002). ONYX-015, an E1B gene-defective adenovirus, induces cell death in human anaplastic thyroid carcinoma cell lines. J. Clin. Endocrinol. Metab. 87, 2525-2531.
28. QIAO, D., MEYER, K., MUNDHENKE, C., DREW, S.A., and FRIEDL, A. (2003). Heparan sulfate proteoglycans as regulators of fibroblast growth factor-2 signaling in brain endothelial cells: Specific role for glypican-1 in glioma angiogenesis. J. Biol. Chem. 278, 16045-16053.
29. REIN, D.T., BREIDENBACH, M., KIRBY, T.O., HAN, T., SIEGAL, G.P., BAUERSCHMITZ, G.J., WANG, M., NETTELBECK, D.M., TSURUTA, Y., YAMAMOTO, M., DALL, P., HEMMINKI, A., and CURIEL, D.T. (2005). A fiber-modified, secretory leukoprotease inhibitor promoter-based conditionally replicating adenovirus for treatment of ovarian cancer. Clin. Cancer Res. 11, 1327-1335.
30. SEKI, T., DMITRIEV, I., SUZUKI, K., KASHENTSEVA, E., TAKAYAMA, K., ROTS, M., UIL, T., WU, H., WANG, M., and CURIEL, D.T. (2002). Fiber shaft extension in combination with HI loop ligands augments infectivity for CAR-negative tumor targets but does not enhance hepatotropism in vivo. Gene Ther. 9, 1101-1108.
31. SHINOURA, N., YOSHIDA, Y., TSUNODA, R., OHASHI, M., ZHANG, W., ASAI, A., KIRINO, T., and HAMADA, H. (1999). Highly augmented cytopathic effect of a fiber-mutant E1B-defective adenovirus for gene therapy of gliomas. Cancer Res. 59, 3411-3416.
32. STABA, M.J., WICKHAM, T.J., KOVESDI, I., and HALLAHAN, D.E. (2000). Modifications of the fiber in adenovirus vectors increase tropism for malignant glioma models. Cancer Gene Ther. 7, 13-19.
33. SUZUKI, K., FUEYO, J., KRASNYKH, V., REYNOLDS, P.N., CURIEL, D.T., and ALEMANY, R. (2001). A conditionally replicative adenovirus with enhanced infectivity shows improved oncolytic potency. Clin. Cancer Res. 7, 120-126.
34. TANGO, Y., TAKI, M., SHIRAKIYA, Y., OHTANI, S., TOKUNAGA, N., TSUNEMITSU, Y., KAGAWA, S., TANI, T., TANAKA, N., and FUJIWARA, T. (2004). Late resistance to adenoviral p53-mediated apoptosis caused by decreased expression of coxsackie-adenovirus receptors in human lung cancer cells. Cancer Sci. 95, 459-463.
35. TEKANT, Y., DAVYDOVA, J., RAMIREZ, P.J., CURIEL, D.T., VICKERS, S.M., and YAMAMOTO, M. (2005). Oncolytic adenoviral therapy in gallbladder carcinoma. Surgery 137, 527-535.
36. TSAI, V., JOHNSON, D.E., RAHMAN, A., WEN, S.F., LAFACE, D., PHILOPENA, J., NERY, J., ZEPEDA, M., MANEVAL, D.C., DEMERS, G.W., and RALSTON, R. (2004). Impact of human neutralizing antibodies on antitumor efficacy of an oncolytic adenovirus in a murine model. Clin. Cancer Res. 10, 7199-7206.
37. TYLER, M.A., ULASOV, I.V., BOROVJAGIN, A., SONABEND, A.M., KHRAMTSOV, A., HAN, Y., DENT, P., FISHER, P.B., CURIEL, D.T., and LESNIAK, M.S. (2006). Enhanced transduction of malignant glioma with a double targeted Ad5/3-RGD fiber-modified adenovirus. Mol. Cancer Ther. 5, 2408-2416.
38. ULASOV, I.V., TYLER, M.A., ZHENG, S., HAN, Y., and LESNIAK, M.S. (2006). CD46 represents a target for adenoviral gene therapy of malignant glioma. Hum. Gene Ther. 17, 556-564.
39. ULASOV, I.V., TYLER, M.A., ZHENG, S., HAN, Y., and LESNIAK, M.S. (2007a). Targeting adenovirus to CD80/CD86 increases gene transfer efficiency to malignant glioma. J. Neurosurg. (in press).
40. ULASOV, I.V., RIVERA, A.A., SONABEND, A.M., RIVERA, L.B., WANG, M., ZHU, Z.B., and LESNIAK, M.S. (2007b). Comparative evaluation of survivin, midkine, and CXCR4 promoters for transcriptional targeting of glioma gene therapy. Cancer Biol. Ther. (in press).
41. VAN GIJSSEL, H.E., SCHILD, L.J., WATT, D.L., ROTH, M.J., WANG, G.Q., DAWSEY, S.M., ALBERT, P.S., QIAO, Y.L., TAYLOR, P.R., DONG, Z.W., and POIRIER, M.C (2004). Polycyclic aromatic hydrocarbon-DNA adducts determined by semiquantitative immunohistochemistry in human esophageal biopsies taken in 1985. Mutat. Res. 547, 55-62.
42. VAN HOUDT, W.J., HAVIV, Y.S., LU, B., WANG, M., RIVERA, A.A., ULASOV, I.V., LAMFERS, M.L., REIN, D., LESNIAK, M.S., SIEGAL, G.P., DIRVEN, C.M., CURIEL, D.T., and ZHU, Z.B. (2006). The human survivin promoter: A novel transcriptional targeting strategy for treatment of glioma. J. Neurosurg. 104, 583-592.
43. WICKHAM, T.J., TZENG, E., SHEARS, L.L., 2nd, ROELVINK, P.W., LI, Y., LEE, G.M., BROUGH, D.E., LIZONOVA, A., and KOVESDI, I. (1997). Increased in vitro and in vivo gene transfer by adenovirus vectors containing chimeric fiber proteins. J. Virol. 71, 8221-8229.
44. WU, H., HAN, T., LAM, J.T., LEATH, C.A., DMITRIEV, I., KASHENTSEVA, E., BARNES, M.N., ALVAREZ, R.D., and CURIEL, D.T. (2004). Preclinical evaluation of a class of infectivity-enhanced adenoviral vectors in ovarian cancer gene therapy. Gene Ther. 11, 874-878.
45. YAMADA, Y., KUROIWA, T., NAKAGAWA, T., KAJIMOTO, Y., DOHI, T., AZUMA, H., TSUJI, M., KAMI, K., and MIYATAKE, S. (2003). Transcriptional expression of survivin and its splice variants in brain tumors in humans. J. Neurosurg. 99, 738-745.
46. ZHU, Z.B., CHEN, Y., MAKHIJA, S.K., LU, B., WANG, M., RIVERA, A.A., YAMAMOTO, M., WANG, S., SIEGAL, G.P., CURIEL, D.T., and McDONALD, J.M. (2006). Survivin promoter-based conditionally replicative adenoviruses target cholangiocarcinoma. Int. J. Oncol. 29, 1319-1329.